Oruka Therapeutics Reports $30.3 Million Net Loss in Q3 2025, Increases Cash Reserves to $500.9 Million

Oruka Therapeutics, Inc. reported a net loss of $30.3 million for the third quarter of 2025, a 6% increase from the $28.6 million loss recorded in the same period of the previous year. For the nine months ending September 30, 2025, the company’s net loss reached $75.9 million, compared to $57.9 million for the period from its inception on February 6, 2024, to September 30, 2024. The increase in losses is attributed to rising operating expenses, which totaled $34.1 million for the third quarter, up 16% from $29.4 million in the prior year. Research and development expenses rose by 13% to $29.0 million, while general and administrative expenses increased by 36% to $5.1 million.

The company’s financial position showed significant changes compared to the previous fiscal period. As of September 30, 2025, Oruka had cash, cash equivalents, and marketable securities totaling $500.9 million, a substantial increase from $396.0 million at the end of 2024. This increase is primarily due to successful financing activities, including a $169.6 million net proceeds from the 2025 PIPE Financing completed in September 2025. The company’s total assets increased to $509.3 million, while total liabilities rose to $22.5 million, reflecting a significant increase in operational capacity and financial resources.

Strategically, Oruka has focused on advancing its clinical programs, particularly ORKA-001 and ORKA-002, which target IL-23 and IL-17A/F, respectively. The company initiated a Phase 2a clinical trial for ORKA-001 in patients with moderate-to-severe psoriasis in the third quarter of 2025 and plans to begin a Phase 2b trial in early 2026. Additionally, the company has expanded its workforce to support these initiatives, with personnel-related expenses increasing significantly. As of September 30, 2025, Oruka had 48.4 million shares of common stock outstanding, reflecting its growth and capital-raising efforts.

Looking ahead, Oruka anticipates continued increases in research and development expenses as it progresses through clinical trials and prepares for potential commercialization of its product candidates. The company expects its existing cash reserves will be sufficient to fund operations for at least the next twelve months. However, it acknowledges the need for additional financing to support ongoing and future development activities. The management remains optimistic about the potential of its pipeline and the strategic partnerships established, which are expected to enhance its market position in the biopharmaceutical industry.